Rhabdomyolysis in COVID-19: Report of Four Cases

Balraj Singh 1, Parminder Kaur 2, Ashesha Mechineni 3, Michael Maroules 4

1. Hematology/Oncology, Saint Joseph’s University Medical Center, Paterson, USA 2. Cardiology, Saint Joseph’s University Medical Center, Paterson, USA 3. Internal Medicine, Saint Joseph’s University Medical Center, Paterson, USA 4. Hematology/Oncology, Saint Joseph’s University Medical Center, Paterson, USA

Corresponding author: Balraj Singh, hrsri9@gmail.com

Abstract

Coronavirus disease 2019 (COVID-19) is a global public health emergency. COVID-19 is most well known for affecting the respiratory system, although it can also result in several extrapulmonary manifestations. Limited literature is available regarding rhabdomyolysis in COVID-19. We report four cases of rhabdomyolysis in COVID-19 patients. High index of suspicion is required for the appropriate clinical scenario to recognize this life-threatening situation so that complications can be avoided.

Categories: Internal Medicine, Infectious Disease, Rheumatology

Keywords: covid 19, sars-cov-2 (severe acute respiratory syndrome coronavirus -2), rhabdomyolysis, viral myositis, coronavirus, coronavirus disease, atypical presentation

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the coronavirus disease 2019 (COVID-19), has infected millions of people and has caused more than hundreds of thousands of deaths globally. COVID-19 can present with a spectrum of clinical manifestations, including fever, myalgia, cough, dyspnea, and less frequently headache, diarrhea, nausea, and vomiting [1]. Although respiratory symptoms predominate, widespread organ-specific manifestations of COVID-19 are increasingly being reported. We report four cases of rhabdomyolysis in COVID-19.

Case Presentation

COVID-19 was diagnosed by nasopharyngeal swab real-time reverse transcription polymerase chain reaction (RT-PCR). Relevant clinical characteristics and laboratory values of the four cases are summarized in Table 1. All patients had elevated creatine kinase at presentation.
| Variable                                          | Case 1       | Case 2       | Case 3       | Case 4       |
|--------------------------------------------------|--------------|--------------|--------------|--------------|
| Age                                              | 67           | 29           | 43           | 70           |
| Sex                                              | Male         | Male         | Male         | Male         |
| History of alcohol abuse/substance abuse/trauma/exertion | None         | None         | None         | None         |
| Influenza/parainfluenza/enterovirus/adenovirus      | Negative     | Negative     | Not done     | Not done     |
| Home medications                                  | None         | Amlodipine, clonidine, hydrochlorothiazide, furosemide | Hydralazine  | None         |
| Intubated                                         | Yes          | Yes          | No           | Yes          |
| CK at presentation (U/L)                          | 589          | 4,330        | 8,630        | 5,006        |
| Peak CK                                           | 19,773       | 4,330        | 9,793        | 5,006        |
| Day of hospitalization corresponding to peak CK   | Day 4        | Day 1        | Day 2        | Day 1        |
| WBC (K/mm$^3$)                                    | 8.7          | 8.2          | 8.2          | 11.8         |
| Hemoglobin (g/dL)                                 | 13.4         | 14.9         | 11.8         | 15.7         |
| Platelets (K/mm$^3$)                              | 101          | 156          | 115          | 147          |
| Troponin (ng/mL)                                  | 0.02         | 0.4          | 0.4          | 0.3          |
| Sodium (mEq/L)                                    | 139          | 134          | 134          | 144          |
| Potassium (mEq/L)                                 | 4            | 4            | 5.1          | 3.5          |
| Phosphorous (mg/dL)                               | 3.8          | ND           | 8.8          | 3.5          |
| BUN (mg/dL)                                       | 18           | 57           | 74           | 32           |
| Creatinine (mg/dL)                                | 1.16         | 3.8          | 20           | 1.68         |
| Acute renal replacement therapy                   | Yes          | No           | No           | No           |
| AST (U/L)                                         | 46           | 121          | 142          | 179          |
| ALT (U/L)                                         | 60           | 66           | 43           | 53           |
| ESR (mm/hr)                                       | 53           | 40           | 94           | 63           |
| CRP (mg/L)                                        | 157.9        | 86.5         | 249          | 363.3        |
| Ferritin (ng/mL)                                  | 574          | 1,170        | 5,217        | 1,760        |
| LDH (U/L)                                         | 459          | 907          | 478          | 1475         |
| D-dimer                                          | 6.62         | 1.92         | 1.96         | 3.11         |
| Urinalysis blood                                  | ND           | Large blood  | ND           | Large blood  |
| Urinalysis red blood cells (per HPF)               | ND           | 4-5          | ND           | No red blood cells |
| Outcome                                           | Died         | Died         | Died         | Died         |

**TABLE 1: Clinical characteristics and laboratory values of the four cases**

Reference ranges are as follows: CK 30-223 unit/L, white cell count 4.5-11 K/mm$^3$, hemoglobin 12-16 g/dL, platelets 140-440 K/mm$^3$, troponin less than 0.03 ng/ml, sodium 135-145 mEq/L, potassium 3.5-5 mEq/L, phosphorous 2.5-5 mg/dL, BUN 7-23 mg/dL, creatinine 0.6-1.30 mg/dL, aspartate transaminase 13-39 U/L, alanine transaminase 7-52 U/L, ESR 0-32 mm/hr, CRP less than 10 mg/L, ferritin 12-300 ng/mL, LDH 140-271 U/L, d-dimer less than 0.5, urinalysis blood negative, urinalysis red blood cells 0-3/HPF.

CK, creatine kinase; BUN, blood urea nitrogen; AST, aspartate transaminase; ALT, alanine transaminase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LDH, lactate dehydrogenase; ND, not done; HPF, high power field.

**Case 1**

A 67-year-old male patient with a past medical history of hypertension presented to the emergency...
department complaining of fever and shortness of breath. On initial examination, the patient was in severe respiratory distress, tachypneic, using accessory muscles, saturating at approximately 80% on room air, and was intubated. Figure 1 shows the creatine kinase levels corresponding to the day of hospitalization.

Chest X-ray performed at baseline showed bilateral hazy infiltrates. Chest CT showed extensive ground-glass opacity and consolidation in the lungs bilaterally. The patient was started on azithromycin, ceftriaxone, hydroxychloroquine, and fluids. On day 3, the patient developed acute renal failure and was started on hemodialysis. The patient had a complicated hospital course, requiring ventilatory support throughout the hospitalization and unfortunately passed away on day 21.

Case 2
A 39-year-old male patient with a history of hypertension presented to the emergency department with fever, muscle aches, shortness of breath, and altered mental status. On initial examination, the patient was in severe respiratory distress, tachypneic, using accessory muscles, hypoxic, and was intubated. Urinalysis was positive for large blood with four to five red blood cells (reference: 0-3) seen microscopically. Chest X-ray showed extensive confluent bilateral pulmonary infiltrates. The patient passed away due to cardiac arrest on day 1.

Case 3
A 45-year-old male patient with a past medical history of end-stage renal disease on hemodialysis comes to the emergency room with complaints of cough, shortness of breath muscle aches, and fever of two days of duration. Vital signs on presentation were heart rate of 107 beats per minute, blood pressure of 94/61 mm Hg, oxygen saturation 99% on room air, and temperature of 37.1 degree Celsius. On physical examination, diffuse bilateral rhonchi were present. Figure 2 shows the creatine kinase levels corresponding to the day of hospitalization.
FIGURE 2: Creatine kinase levels corresponding to the day of hospitalization

Chest x-ray showed multifocal ill-defined parenchymal opacities bilaterally, most notably over mid and lower lung zones with increased interstitial thickening. The patient was started ceftriaxone, hydroxychloroquine, and azithromycin. The patient passed away due to cardiac arrest on day 2.

Case 4

A 70-year-old male patient with no significant past medical history presented to the emergency department with chief complaints of shortness of breath and cough of eight days of duration. Vital signs on presentation were heart rate of 101 beats per minute, blood pressure of 94/61 mm Hg, respiratory rate 20 breaths per minute, oxygen saturation 87% on room air, and temperature of 37.2 degree Celsius. The patient was intubated due to worsening respiratory status. Figure 3 shows the creatine kinase levels corresponding to the day of hospitalization.

Urinalysis was positive for large blood with no red blood cells seen microscopically. Chest x-ray showed bilateral hazy infiltrates throughout both lung fields. The patient was treated with fluids, intravenous methylprednisolone 40 mg q12 hours, and ceftriaxone. Hydroxychloroquine and azithromycin were not started due to prolonged corrected Q-T interval of 503 ms. The patient was extubated on day 8; however, he required reintubation on day 11. The patient had a complicated hospital course - septic shock, gastrointestinal bleed, and after discussion with the patient’s family, he was made comfort care and died on day 17.

Discussion

Rhabdomyolysis is described as the rapid breakdown of skeletal muscles resulting in release of cell degradation products and intracellular elements within the bloodstream and extracellular space. Rhabdomyolysis can be caused by multiple etiologies, such as trauma, marked exertion in untrained individuals, hyperthermia, metabolic myopathies, drugs or toxins, infections, or electrolyte disorders [2]. The usual symptoms include muscle pain, weakness, and dark urine. The laboratory diagnosis is based on the measurement of creatine kinase in serum or plasma. A prompt diagnosis is a prerequisite for successful treatment and avoiding complications. Identification of the triggering event is of paramount importance. Early and aggressive fluid resuscitation is the cornerstone of management. Potential complications of rhabdomyolysis include fluid and electrolyte abnormalities, kidney failure, liver injury, cardiac arrhythmias, compartment syndrome, and disseminated intravascular coagulation [3].

Viruses that have been associated with rhabdomyolysis include influenza, parainfluenza, coxsackievirus, Epstein-Barr, herpes simplex, adenovirus, echovirus, human immunodeficiency virus, and cytomegalovirus [4,5]. Case reports of SARS-CoV-2 causing rhabdomyolysis have been described. Rhabdomyolysis has been described both as a presenting feature and a late complication of COVID-19. Chedid et al. described a case of a 51-year-old male patient with severe rhabdomyolysis leading to acute kidney injury (AKI) as the primary presenting feature of COVID-19 [6]. Jin and Tong reported a 60-year-old...
man with COVID-19, who was found to have rhabdomyolysis on day 9 of hospitalization when he developed pain and weakness of his lower extremities [7]. Possible mechanisms of action of viral-induced myositis include direct viral invasion or myotoxic cytokines or immune mediated [8,9]. Further studies are needed to understand the pathogenesis.

Conclusions

We report four cases of rhabdomyolysis in COVID-19 patients. Our cases add to the limited literature regarding rhabdomyolysis in COVID-19. Clinicians should be aware of the life-threatening manifestation of COVID-19 so that timely diagnoses can be made, and complications avoided.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382:1708-1720. 10.1056/NEJMoa2002052
2. Cervellin G, Cornelli I, Lippi G: Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010, 48:749-756. 10.1515/cclm.2010.151
3. Torres PA, Helmstetter JA, Kaye AM, Kaye AD: Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015, 15:58-69.
4. Crum-Cianflone NF: Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008, 21:473-494. 10.1128/CMR.00001-08
5. Ayala E, Kagawa FT, Welmer IH, Tam J, Upadhayay D: Rhabdomyolysis associated with 2009 influenza A(H1N1). JAMA. 2009, 302:1863-1864. 10.1001/jama.2009.1582
6. Chedid NR, Udit S, Soljhuj Z, Patanwala MY, Barkoudah E: COVID-19 and rhabdomyolysis [Epub ahead of print]. J Gen Intern Med. 2020, 1-4. 10.1007/s11606-020-06059-y
7. Jin M, Tong Q: Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis. 2020, 26:1618-1620. 10.3201/eid2607.200445
8. Naylor CD, Jevnikar AM, Witt NJ: Sporadic viral myositis in two adults. CMAJ. 1987, 137:819-821.
9. Fodili F, van Bommel EF: Severe rhabdomyolysis and acute renal failure following recent Coxsackie B virus infection. Neth J Med. 2005, 61:177-179.